Soligenix Inc (SNGX)

[io_io]

<"probably didn't have any answer for the differential (and inconsistent between trials) effect in myelos vs. non-myelos">



I don't think they expected the ODAC / FDA to go sub-group-mining, because that is a no-no. But anyway they submitted a Phase II trial, with all myelos, and you have much the same benefit.


By the way, I suspect that one analysis submitted late may have been for Steroid Failure in myelos v non-myelos in the Phase III. At ODAC, I think it was Tim Rodell said that in this analysis there was benefit to both sub-groups in that trial.